Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- The George Institute
- Target Recruit Count
- 994
- Registration Number
- NCT05345327
- Locations
- 🇦🇺
Monash University, Melbourne, Victoria, Australia
🇱🇰National Hospital - Galle, Galle, Southern Province, Sri Lanka
🇱🇰National Hospital of Sri Lanka 1, Colombo 10, Sri Lanka
The Effect of Inflammation in Heart Failure
- Conditions
- Interventions
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT05266404
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-16
- Target Recruit Count
- 120
- Registration Number
- NCT05262257
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT05250011
- Locations
- 🇮🇹
Research Site, Napoli, Italy
Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Kaohsiung Medical University
- Target Recruit Count
- 225
- Registration Number
- NCT05196347
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT05194592
- Locations
- 🇰🇷
Yonsei University Wonju College of Medicine, Wonju, Gangwondo, Korea, Republic of
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Boston University
- Target Recruit Count
- 50
- Registration Number
- NCT05139914
- Locations
- 🇺🇸
BU School of Medicine Evans 748, Boston, Massachusetts, United States
Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT05058859
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Youngene Therapeutics Inc., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04956263
- Locations
- 🇺🇸
ProSciento, Inc, Chula Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.